CUSIP: 114082100
Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,485,518
-
Share change
-
+5,959,358
-
Total reported value
-
$52,120,000
-
Put/Call ratio
-
36%
-
Price per share
-
$4.17
-
Number of holders
-
53
-
Value change
-
+$24,216,590
-
Number of buys
-
32
-
Number of sells
-
17
Quarterly Holders Quick Answers
What is CUSIP 114082100?
CUSIP 114082100 identifies BTX - BROOKLYN IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2022
-
Previous quarter:
Q3 2021
Recent filing periods for CUSIP 114082100:
Institutional Holders of BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) as of Q4 2021
As of 31 Dec 2021,
BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,485,518 shares.
The largest 10 holders included
BlackRock Inc., Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, VANGUARD GROUP INC, INVERNESS COUNSEL LLC /NY/, JPMORGAN CHASE & CO, MORGAN STANLEY, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
53
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.